Welcome to our dedicated page for ChromaDex Corporation news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.
ChromaDex Corporation (NASDAQ: CDXC) is a pioneering global nutraceutical company dedicated to enhancing healthy aging through scientific advancements. The company's mission revolves around improving the way people age by focusing on the potential of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in metabolic processes that declines with age.
ChromaDex's team of scientists partners with renowned universities and research institutions worldwide to explore and develop innovative, science-based ingredients. Their flagship product, Tru Niagen®, is a supplement that features Niagen® (nicotinamide riboside), an NAD+ precursor aimed at promoting better aging. Alongside Tru Niagen®, ChromaDex's product portfolio includes PteroPure® (pterostilbene), PureEnergy® (a caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).
The company operates through three primary segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The majority of ChromaDex's revenue is generated from its Consumer Products segment, driven by the popularity and efficacy of Tru Niagen®.
ChromaDex's commitment to scientific research is evident in its numerous collaborations with academic institutions. These partnerships aim to uncover the full potential of NAD+ and other beneficial compounds to develop products that support health and longevity.
The company's stock is publicly traded on NASDAQ under the symbol CDXC. For more information on ChromaDex, visit their website at www.chromadex.com, follow them on Twitter @chromadex, or like their Facebook page here.
Recent Achievements and Current Projects:
- Continued research and development into NAD+ and its related compounds.
- Expansion of Tru Niagen® into new markets globally.
- Ongoing partnerships with leading universities and research institutions.
- Innovative new product launches aimed at further promoting healthy aging.
ChromaDex Corp. (NASDAQ:CDXC) announced promising results from a Phase II clinical study on their patented nicotinamide riboside (NR) ingredient, Niagen®. Conducted with Northwestern University Feinberg School of Medicine, the study revealed significant improvements in functional mobility for individuals with peripheral artery disease (PAD). Participants showed increased six-minute walking distance and treadmill walking time, compared to a placebo. These findings, now published in Nature Communications, indicate the potential of NR to benefit PAD patients. However, further confirmation through larger clinical trials is necessary.
ChromaDex is set to launch Niagen+, the first pharmaceutical-grade intravenous and injectable Niagen (Nicotinamide Riboside Chloride or NRC).
FDA-approved for compounding by 503B outsourcing facilities, Niagen+ IV and injectable forms will be available at clinics nationwide starting August 2024. A clinical study showed no adverse side effects, superior tolerability, and a faster infusion time compared to NAD+ IV, with blood NAD+ levels peaking higher and sooner.
Niagen+ aims to transform the $2.32 billion global intravenous hydration therapy market. ChromaDex holds over 80 patents for its NAD+ precursors, ensuring robust IP protection.
ChromaDex (NASDAQ: CDXC) has received Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation from the FDA for its product candidate Nicotinamide Riboside Chloride (NRC), aimed at treating Ataxia Telangiectasia (AT), a rare and life-threatening condition affecting children. The company intends to submit an Investigational New Drug (IND) application to the FDA to commence human clinical trials. These trials will be led by Dr. Vilhelm Bohr, a scientific advisor to ChromaDex. The designations could accelerate NRC's development and provide benefits like market exclusivity and tax credits. CEO Rob Fried highlighted the potential of NRC to address unmet medical needs in rare diseases, which affect over 30 million people in the U.S.
ChromaDex (NASDAQ: CDXC) will participate in Renmark Financial Communications Inc.'s Virtual Non-Deal Roadshow on June 11, 2024, at 2:00pm PST. The event will feature presentations from CEO Rob Fried and CFO Brianna Gerber, who will discuss the latest investor presentation and participate in a live Q&A session. Stakeholders and investors are encouraged to register for the live event, though access may be A replay will be available on the ChromaDex Investor Relations website. For further details, visit www.chromadex.com.
ChromaDex (NASDAQ: CDXC) will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company's CEO, Rob Fried, and CFO, Brianna Gerber, will engage in virtual one-on-one meetings throughout the event. Interested parties can arrange meetings by contacting Lytham Partners or registering on their website.
ChromaDex (NASDAQ:CDXC) announced that its Niagen® ingredient has won the NutraIngredients EU Healthy Ageing Ingredient of the Year Award. Niagen, a patented nicotinamide riboside (NR) and the active ingredient in Tru Niagen®, was recognized for its high-quality research and significant contributions to healthy aging. The award highlights Niagen’s impact on cellular health and its potential to support longevity across various generations. ChromaDex's CEO, Rob Fried, expressed honor in receiving the award, emphasizing their mission to tackle aging through NAD+ augmentation. Niagen is backed by extensive research, including studies from two Nobel Prize winners and over 300 published scientific papers.
ChromaDex (NASDAQ:CDXC) reported first quarter 2024 financial results with total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million, and positive Adjusted EBITDA of $0.7 million. The company reiterated a full-year outlook with net sales growth of at least 16%. Tru Niagen® contributed $17.4 million to total net sales, and ChromaDex expanded distribution through partnerships with The Vitamin Shoppe and Sprouts Farmers Market. Operating expenses decreased, net loss improved, and Adjusted EBITDA turned positive. The company aims for revenue growth, gross margin improvement, and increased investments in research and development, marketing, and product launches.
ChromaDex announces an ingredient partnership with Solgar, a Nestlé Health Science brand, introducing Solgar Cellular Energy supplement featuring ChromaDex's NIAGEN NR. The collaboration aims to boost NAD+ levels for cellular health, highlighting NIAGEN as the gold standard in NAD+ supplements. NIAGEN NR, supported by extensive research, increases NAD+ by over 50% in two weeks. Solgar Cellular Energy also includes B vitamins and vitamin C for comprehensive health benefits.
FAQ
What is the current stock price of ChromaDex Corporation (CDXC)?
What is the market cap of ChromaDex Corporation (CDXC)?
What is ChromaDex Corporation's main focus?
What is Tru Niagen®?
How does ChromaDex generate most of its revenue?
On which stock exchange is ChromaDex traded?
What are some of ChromaDex's other products?
Who are ChromaDex's research partners?
What is NAD+?
Where can I find more information about ChromaDex?
Does ChromaDex offer services apart from consumer products?
How is ChromaDex contributing to healthy aging research?
